Notice2021-12182
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 10, 2021
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 110 (Thursday, June 10, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 110 (Thursday, June 10, 2021)]
[Notices]
[Pages 30966-30967]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-12182]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Benjamin Hurley; tel. 240-669-5092;
<a href="/cdn-cgi/l/email-protection#385a5d56525955515616504d4a545d4178565150165f574e"><span class="__cf_email__" data-cfemail="ea888f84808b878384c4829f98868f93aa848382c48d859c">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Producing Modified Vaccinia Ankara (MVA) Virus with Continuous
Mammalian Cell Lines: Viral Host-range Factors for Increasing MVA
Vaccine Production Yield Description of Technology:
Modified vaccinia Ankara (MVA) based vaccines are being deployed in
numerous human clinical trials for indications such as measles,
malaria, HIV-1 and MERS to name a few. As with many vaccines, scale-up
and production are significant challenges with the MVA platform. Not
only are current large-scale MVA vaccine production processes
inefficient (such as the cumbersome use of chick embryo fibroblast
(CEF) cells), but a major bottleneck lies in limited host cell
propagation options and a lack of viable continuous cell lines suitable
for MVA vaccine production.
To address this need, scientists at NIAID have identified a number
of key viral factors in MVA replication in mammalian cells and
developed methods of modifying MVA viruses in a way that allows for the
growth of MVA in cells that were previously considered unsuitable for
such purpose. For example, NIAID scientists observed that the
introduction of a serine protease inhibitor 1 (SPI-1) gene into the MVA
genome led to more than a 2-log enhancement of virus spread in human
diploid MRC-5 cells, whereas deletion of the gene diminished the spread
of host-range extended viruses by similar extents. Additionally, MRC-5
cells stably expressing SPI-1 also enhanced replication of MVA.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Vaccine Development: Recombinant MVA-based vaccine
production in non-CEF cell lines.
<bullet> Therapeutic oncolytic virus: Recombinant MVA constructs
encoding oncolytic tumor-suppressor proteins, pro-apoptotic proteins,
cytokines, immunomodulatory proteins, cytotoxic peptides, suicide
proteins, cytotoxins, pro-drugs, therapeutic RNAs, etc.
Competitive Advantages:
<bullet> Recombinant MVA constructs for use in non-avian, continual
cell line-mediated vaccine production.
<bullet> Efficient scale-up vaccine production as a result of
higher viral yield, enhancing epidemic/pandemic preparedness.
Inventors: Bernard Moss, Linda Wyatt, Ruikang Liu, Jorge Mendez-
Rios, all of NIAID.
Publications:
Liu R, Mendez-Rios JD, Peng C, et al. SPI-1 is a missing host-range
factor required for replication of the attenuated modified vaccinia
Ankara (MVA) vaccine vector in human cells.; PLoS Pathog. 2019.
Peng C, Moss B. Repair of a previously uncharacterized second host-
range gene contributes to full replication of modified vaccinia
virus Ankara (MVA) in human cells. Proc Natl Acad Sci U S A. 2020.
Intellectual Property: HHS Reference No. E-076-2019; International
Application No. PCT/US20/33788.
Licensing Contact: To license this technology, please contact
Benjamin
[[Page 30967]]
Hurley at 240-669-5092 or <a href="/cdn-cgi/l/email-protection#e78582898d868a8e89c98f92958b829ea7898e8fc9808891"><span class="__cf_email__" data-cfemail="bfdddad1d5ded2d6d191d7cacdd3dac6ffd1d6d791d8d0c9">[email protected]</span></a>, and reference E-076-
2019.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this invention. For collaboration
opportunities, please contact Benjamin Hurley; (240) 669-5092,
<a href="/cdn-cgi/l/email-protection#187a7d76727975717636706d6a747d6158767170367f776e"><span class="__cf_email__" data-cfemail="4b292e25212a26222565233e39272e320b252223652c243d">[email protected]</span></a>.
Dated: June 2, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-12182 Filed 6-9-21; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 10, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.